AI in the Men's-Health Funnel
Algorithmic Prescribing, Automated Consultations, and the Regulatory Questions
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Prescribing is regulated by state medical/pharmacy boards, DEA, FTC
Reference only. Not medical advice.
What can go wrong
Under-screening can mean missing contraindications, starting testosterone without confirming low levels or counseling on fertility loss, or prescribing where lifestyle or a different diagnosis was the real issue. 'Negative option' subscription billing (easy to start, hard to cancel) was a specific FTC concern. Sensitive intake data also feeds the privacy risks documented elsewhere in this library.
This is something to take to a clinician. The Atlas can tell you what is known about ai in the men's-health funnel in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Many direct-to-consumer men's-health platforms run an 'asynchronous' model: the patient fills out a questionnaire, and a clinician (or, increasingly, algorithm-assisted workflows) reviews it and issues a prescription without a live visit. For appropriate, low-risk medications this can expand access. The concern is that some funnels are engineered to convert: questionnaires that are difficult to fail, default selections that steer toward the product, and clinician review that is fast and largely confirmatory. Layering AI on top (automated triage, suggested prescriptions, chat that nudges toward purchase) intensifies both the access benefit and the commercial-incentive risk. The Cerebral matter and journalistic investigations into stimulant and other prescribing highlighted how automated, growth-driven prescribing can go wrong. This entry describes documented industry patterns and regulatory questions.
When the 'consultation' is a form that almost always says yes.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
In a conversion-optimized funnel, the questionnaire collects just enough to support a prescription while minimizing drop-off. Branching logic routes users toward an eligible product; contraindication screening may be present but is sometimes thin. A clinician reviews asynchronously, often handling high volumes, and approves the majority. AI can pre-screen, draft the clinician's note, suggest the prescription, and run the chat that overcomes objections. The financial model frequently depends on subscription conversion, which creates pressure pointing toward 'yes.'
The incentive the funnel hides
A genuine clinical consultation can end in 'no' or 'this is not appropriate for you.' A funnel built for growth is measured by conversion rate and lifetime value. Those metrics reward making it easy to get a prescription, not making it easy to be screened out. For testosterone, this is especially fraught: appropriate TRT requires confirmed low morning testosterone on at least two tests, symptom correlation, and baseline labs (hematocrit, PSA), plus fertility counseling, because exogenous testosterone suppresses sperm production. A funnel that prescribes on a single questionnaire or a single low reading is not following guideline-concordant care.
Safety in detail
Testosterone therapy and other prescription interventions involve significant physiological effects and require evaluation and monitoring by a qualified physician. A questionnaire-based 'consultation' is not a substitute for guideline-concordant screening, and self-directed dose escalation carries documented health risks.
What it does to fertility
Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and can sharply reduce sperm production, sometimes to azoospermia; this may not be fully reversible. Funnels that omit fertility counseling are a documented gap, especially for men of reproductive age.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- For any testosterone therapy: confirmed repeat morning total testosterone before starting
- Baseline and follow-up hematocrit
- Baseline PSA and prostate assessment per age/risk
- Fertility counseling before initiation
- Symptom reassessment rather than dose-chasing numbers
What people get wrong
Often saidAn online consult means a doctor carefully evaluated me
ActuallyIn high-volume asynchronous models, review can be fast and largely confirmatory. The depth of evaluation varies enormously by platform and is not guaranteed by the word 'consultation.'
Often saidAI-assisted prescribing is more objective
ActuallyAI can encode the platform's commercial incentives. An algorithm tuned to conversion is not a neutral clinical second opinion.
Often saidIf they will prescribe it to me, it must be appropriate
ActuallyWillingness to prescribe in a DTC funnel reflects business model and eligibility logic, not necessarily that the therapy is right for your health or that proper screening occurred.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- Should asynchronous prescribing of testosterone require confirmed repeat labs by rule, not just by platform policy?
- How will regulators treat AI-suggested prescriptions and AI-drafted clinical notes?
- Will state boards converge on standards for conversion-optimized telehealth funnels?
At a glance
- Model
- Asynchronous questionnaire-based prescribing
- Commercial tension
- Funnel optimized to convert vs. to screen
- Cautionary case
- Cerebral (stimulant prescribing scrutiny, FTC action)
- Regulators
- State boards, DEA, FTC, FDA (for products)
- AI's role
- Triage, suggested Rx, conversion-optimized chat
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about AI in the Men's-Health Funnel. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
FTC v. Cerebral2024
Alleged the telehealth company prioritized growth, used hard-to-cancel 'negative option' billing, and disclosed sensitive data; settlement included a $7M penalty and data-use restrictions
Investigative reporting on telehealth stimulant prescribing2022-2023
Reporting (Wall Street Journal, Bloomberg, others) described aggressive, growth-driven prescribing practices at some telehealth startups, prompting pharmacy and regulatory scrutiny
Endocrine Society / AUA TRT guidancevarious
Recommend confirmed low testosterone on repeat morning testing plus symptoms before initiating therapy, with baseline and ongoing monitoring